Request Demo

Last update 31 Jul 2026

Naltrexone

Last update 31 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryNaltrexone, an opioid antagonist, has been utilized for treating addiction to both drugs and alcohol. VIVITROL, a medication containing naltrexone, is approved for patients with alcohol dependence who can abstain from alcohol before medication initiation. At the initial administration of VIVITROL, patients must not be actively drinking. Following opioid detoxification, VIVITROL can also be utilized to prevent relapse to opioid dependence. It is vital to keep in mind that VIVITROL should be incorporated into a comprehensive management program that includes psychosocial support. Naltrexone works by blocking opioid receptors, specifically the mu/kappa/delta receptors, thus preventing the effects of opioids. Unlike buprenorphine and methadone that activate opioid receptors to suppress cravings, naltrexone binds and blocks opioid receptors, reducing opioid cravings. Moreover, it does not cause withdrawal symptoms upon discontinuation and does not possess abuse and diversion potential.

Drug Type

Small molecule drug

Synonyms

DBR-LDN, Naltrexone implant, naltrexone implant(Drug Delivery Company)

+ [11]

Target

Opioid receptors

Action

antagonists

Mechanism

Opioid receptors antagonists(Opioid receptors antagonists)

Therapeutic Areas

Other DiseasesDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Opium DependenceAlcoholismMethamphetamine abuse+ [11]

Inactive Indication

Acquired Immunodeficiency SyndromeAcral Lentiginous Malignant MelanomaAlcohol-Related Disorders+ [33]

Originator Organization

Alkermes, Inc.

Active Organization

Yale University

The Children's Mercy Hospital

University of California, Los Angeles

+ [12]

Inactive Organization

Hershey Medical Center

Shenzhen Civil Life Science Co., Ltd.

The University of Chicago

+ [11]

License Organization

Statera Biopharma, Inc.

Aardvark Therapeutics, Inc.

Scilex Pharmaceuticals, Inc.

+ [9]

Drug Highest PhaseApproved

First Approval Date

United States (13 Apr 2006),

Alcoholism

RegulationOrphan Drug (United States), Priority Review (China)

Structure/Sequence

Molecular FormulaC20H23NO4

InChIKeyDQCKKXVULJGBQN-XFWGSAIBSA-N

CAS Registry16590-41-3

162

Clinical Trials associated with Naltrexone

NCT07249554

/ Not yet recruitingPhase 2IIT

Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder

This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.

Start Date01 Sep 2026

Sponsor / Collaborator

The Johns Hopkins University

NCT07285473

/ Not yet recruitingPhase 2IIT

Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Dose-Finding

This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.

Start Date01 Sep 2026

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT07064564

/ RecruitingPhase 1

A Randomized, Active-comparator Controlled, Two-Dose-level Study of iSTEP-N in Healthy Adults With Long Term Safety and PK Follow-up

This Phase 1b clinical study is evaluating iSTEP-N, an investigational extended-release implant containing naltrexone, a medication used to block the effects of opioids. The implant is placed under the skin of the thigh and is designed to release medication continuously over many months.
The main purpose of the study is to measure blood levels of naltrexone over time after administration of two different doses of the iSTEP-N implant and to compare those levels with the blood levels achieved by Vivitrol®, an FDA-approved injectable extended-release naltrexone given once every month.
The study will enroll healthy adult volunteers aged 18 to 65 years. Participants will be randomly assigned to one of three groups:
* Low-dose iSTEP-N implant
* High-dose iSTEP-N implant
* Monthly Vivitrol injections
Participants will be followed closely for approximately 12 months to measure medication levels and monitor safety, side effects, and overall health. The study will help determine whether the iSTEP-N implant can maintain naltrexone levels comparable to or higher than those achieved with monthly injections, especially during periods when protection from relapse is most important.
Participants who receive an iSTEP-N implant and still have detectable implant material or measurable medication levels at the end of the first year may continue in a long-term follow-up period lasting up to two additional years. During this period, researchers will monitor how long the implant remains detectable and how long medication continues to be released. If the implant remains after two years, participants may choose to have it surgically removed or simply end study participation.
The study is sponsored by Akyso Therapeutics, LLC, with clinical operations conducted at a dedicated clinical research center and oversight provided by an independent Institutional Review Board. All participants undergo screening examinations to confirm eligibility and are carefully monitored throughout participation.
Results from this study will help determine the appropriate dose of iSTEP-N for future clinical trials and support development of long-acting treatment options for opioid use disorder that may reduce the need for frequent injections.

Start Date25 Jul 2026

Sponsor / Collaborator

UAB Ardena

[+2]

100 Clinical Results associated with Naltrexone

100 Translational Medicine associated with Naltrexone

100 Patents (Medical) associated with Naltrexone

8,363

Literatures (Medical) associated with Naltrexone

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Modulation of mu-opioid pathway for the treatment of pruritus: a systematic review of 1,146 patients

Review

Author: Abu Suleiman, Amro ; Ahmed, Khalid M. A. ; Alnajdawi, Alaa I. ; Moustafa, Ahmed R. A. ; Horton, Emma ; Ahmed, Ahmed M. ; Abdulkader, Dina

BACKGROUND:

Pruritus is a debilitating symptom and conventional therapies often provide incomplete relief. The μ-opioid receptor (MOR) pathway is a key regulator of itch, and μ-pathway-modulating agents are increasingly used off-label for refractory pruritus.

AIM:

This systematic review evaluates the efficacy, safety, and real-world use of μ-opioid pathway modulators for pruritus of dermatologic and systemic origin.

METHODS:

Following PRISMA guidelines (PROSPERO CRD420251207101), a comprehensive search of four databases identified 3,274 records, of which 69 studies met inclusion criteria, comprising 14 randomized controlled trials (RCTs; n = 795) and 55 non-randomized studies (n = 351). Owing to substantial clinical and methodological heterogeneity, findings were narratively synthesized.

RESULTS:

Five RCTs evaluated dermatologic conditions, including atopic dermatitis, prurigo nodularis, chronic urticaria, and lichen planopilaris, while nine RCTs assessed systemic pruritus, predominantly cholestatic and uremic pruritus. RCTs investigated oral or topical naltrexone, intravenous naloxone, nalmefene, and extended-release nalbuphine, with most demonstrating clinically meaningful reductions in pruritus intensity using validated itch scales. Non-randomized studies reported improvement across a wide range of dermatologic and systemic conditions, with adverse events generally mild and well tolerated.

CONCLUSIONS:

Overall, μ-opioid pathway modulators show promising efficacy with acceptable short-term safety across diverse pruritic conditions, although larger high-quality RCTs are required to define optimal dosing and support clinical translation.

01 Oct 2026·Journal of substance use and addiction treatment

Pharmacotherapy for alcohol misuse: Views of patients, providers, and leaders in an Alaska Native healthcare system

Article

Author: Burke, Wylie ; Shaw, Jennifer L ; Dillard, Denise A ; Trinidad, Susan B ; Donovan, Dennis M ; Lillie, Kate M ; Wittman, Lucas T ; Ludman, Evette J

INTRODUCTION:

Alcohol misuse is responsible for a significant public health burden in the United States and remains undertreated despite approved treatments for alcohol misuse such as naltrexone. The current study characterizes the views of stakeholders in an Alaska Native healthcare system regarding pharmacotherapy for alcohol misuse.

METHODS:

A secondary, mixed-methods analysis was conducted using qualitative data from 70 interview participants (patients, providers, and health system leaders) and survey data completed by 944 stakeholders (patients, providers, leadership, and administrative staff).

RESULTS:

Five major themes were identified from the qualitative data: gaps in medication awareness and knowledge, perceived benefits of naltrexone, medication as a component of comprehensive treatment, concerns about pharmacotherapy for alcohol misuse, and the importance of shared decision-making. Survey results found that providers were significantly more likely than other stakeholders to favor the use of medications like naltrexone. Compared to non-AN/AI respondents, AN/AI individuals were less likely to believe that medication can help people achieve sobriety and were more likely to endorse survey statements that (1) strong people don't need medication and (2) people who use medication to support sobriety might be trading one addiction for another. Most respondents did not find medication assisted treatment to be against AN/AI cultural values, with no statistical difference between AN/AI and non-AN/AI survey respondents.

CONCLUSIONS:

Identifying mismatches in stakeholders' attitudes and beliefs can highlight opportunities to increase uptake of effective therapies for alcohol misuse. Concerns about pharmacotherapy among patients as compared to providers and AN/AI individuals as compared to non-AN/AI suggests that under-prescribing may not be the main issue in lack of uptake of naltrexone. These findings suggest the importance of identifying patient beliefs about medication use as well as the need for wraparound services and supports for patients prescribed naltrexone.

01 Oct 2026·Journal of substance use and addiction treatment

Would we, could we? Measuring attitudinal and capacity barriers to supporting recovery housing residents on medication for opioid use disorder

Article

Author: Park, Brandon ; Paschke, Maria ; Mericle, Amy A ; Winograd, Rachel P ; Ghonasgi, Rashmi

BACKGROUND:

Recovery housing provides critical support for individuals with opioid use disorder (OUD), yet residents who use medications for OUD (MOUD) often face barriers to entry and long-term support. No existing validated instruments currently assess these barriers, which can differ by MOUD type and reflect both attitudinal stigma and logistical capacity within recovery housing settings.

METHODS:

We developed and tested two parallel versions (Operator and Resident) of a novel tool, the Recovery Housing Barriers to Medications for Addiction Treatment (RHB-MAT) measure. Item generation was informed by literature review and structured input from current housing operators and residents, resulting in scales addressing attitudinal barriers (for both operators and residents) and capacity barriers (for operators) and MOUD type (buprenorphine, methadone, naltrexone). Surveys were administered to 145 recovery housing operators and 250 residents across the United States. Exploratory and confirmatory factor analyses were conducted to establish dimensionality. Internal consistency, and convergent, divergent, and concurrent criterion validity were examined using established measures of stigma and related constructs.

RESULTS:

Factor analyses supported a multidimensional structure, distinguishing attitudinal barriers across both groups and capacity barriers among operators. Internal consistency across scales was acceptable to strong (α = 0.74-0.92) across all but one subscale. Convergent validity was supported while divergent validity was less consistent. Concurrent criterion validity was generally demonstrated with associations between Operator RHB-MAT scores and their house's unique medication acceptance policies by MOUD type. Overall, residents evidenced higher attitudinal barrier scores than operators.

CONCLUSIONS:

The RHB-MAT represents the first validated measure of MOUD-related barriers in recovery housing, with tailored versions for both operators and residents. This tool can be used in research, policy, and practical quality improvement efforts to identify and address attitudinal and capacity-related barriers that impede access to evidence-based OUD treatment in recovery residences.

319

News (Medical) associated with Naltrexone

23 Jul 2026

·www.einpresswire.com

Asana Recovery Launches ILWU Longshore Rehab Program in Orange County

Confidential outpatient rehab for ILWU longshore workers in Orange County — keep your dispatch, income and privacy while you get sober. You don't have to disappear for 30 days to get sober.” — Mark Shandrow, CEO, Asana Recovery FOUNTAIN VALLEY, CA, UNITED STATES, July 23, 2026 / EINPresswire.com / -- FOUNTAIN VALLEY, Calif. — July 23, 2026 — Asana Recovery, a Joint Commission-accredited outpatient drug and alcohol rehab in Orange County named to Newsweek's Best Addiction Treatment Centers list four years running, today announced a dedicated longshore worker addiction treatment program built specifically for members of the International Longshore and Warehouse Union (ILWU). The ILWU longshore rehab program in Orange County delivers evidence-based treatment for alcohol and drug addiction while protecting the three things longshore workers say they cannot afford to lose: their dispatch priority, their weekly paycheck, and their confidentiality. The waterfront runs on rotating shifts, unpredictable board calls, and physically punishing labor — conditions that leave little room for a 30-to-90-day residential stay far from home. Asana Recovery's Longshore program is designed around that reality. Rather than asking members to disappear, it wraps clinical care around the dispatch hall so workers can practice recovery while keeping their life intact — treatment that fits around the work, not the other way around. "Too many longshore workers wait until they hit rock bottom because they believe getting help means walking away from their livelihood," said a spokesperson for Asana Recovery. "We built this program to break that trade-off. You can be in treatment this week and still protect your registration, your income, and your privacy. Recovery shouldn't cost you your career — and here, it doesn't." A Workforce at Real Risk The dangers of the docks don't end at the terminal gate. Workers who suffer a lost-time occupational injury face roughly 2.9 times the risk of opioid-related dependence, often after downplaying an early injury to protect dispatch priority until the pain crosses the prescription threshold. Maritime workers binge-drink at rates about 28% above the general workforce, and can hold full shift attendance while quietly meeting the criteria for an alcohol use disorder for years. Add the trauma of witnessing crush injuries and fatal equipment accidents, plus rotating shifts that destabilize sleep and prime the brain for chemical coping, and roughly one in three members carries a co-occurring depression alongside opioid use. Asana's program is designed to meet that full clinical picture head-on. Care That Works Around the Dispatch Hall The program is anchored at Asana Recovery's Fountain Valley center — about 25 minutes from the Ports of Los Angeles and Long Beach — with additional outpatient and sober-living sites in Costa Mesa and Huntington Beach. Morning, afternoon, and evening tracks accommodate day, swing, and night dispatch, and members can enter at the level of care that fits and step down as they stabilize: Partial Hospitalization (PHP), Intensive Outpatient (IOP), standard Outpatient (OP), Virtual IOP for California members, and structured sober living. Clinical care combines Medication-Assisted Treatment — Suboxone, monthly Sublocade injections, Vivitrol, and naltrexone — with proven therapies including CBT, DBT, EMDR and trauma-focused care, plus individual, group, family, and couples therapy and full psychiatric support. These medications require no daily clinic visits, unlike methadone programs whose rigid hours are incompatible with dispatch. Because addiction rarely travels alone, Asana's dual-diagnosis model also treats the co-occurring depression, anxiety, PTSD, and trauma that so often drive substance use on the docks. Your Job Is Protected. Your Privacy Is Protected. The program is built on the coverage and legal protections ILWU members already have. Treatment is supported through the Coastwise Indemnity Plan via Blue Shield of California PPO — including outpatient visits, up to five days of inpatient detox, and weekly indemnity benefits that continue during approved care — with coverage extended through Alcohol/Drug Recovery Program (ADRP) authorization. Confidentiality is absolute: an ADRP representative cannot disclose participation to an employer, dispatch, or the PMA without written consent, and federal law (HIPAA and 42 CFR Part 2) bars Asana from releasing any health information without a signed authorization. FMLA provides up to 12 weeks of job-protected leave, and the ADA recognizes opioid and alcohol use disorders as disabilities, so members cannot be terminated for voluntarily entering treatment. How Members Get Started The first call is confidential. Members and their families can reach their regional ADRP representative directly — in the LA/Long Beach region, Tamiko Love (Locals 13, 63, 94, and 26) at (310) 547-9966 — or call Asana Recovery at (949) 763-3440 to verify your ILWU-PMA benefits, typically in about 15 minutes, and complete a same-day phone pre-assessment. Learn more about the ILWU longshore rehab program in Orange County and Asana's broader outpatient rehab options in Orange County online. About Asana Recovery Asana Recovery is a family-owned outpatient addiction and mental health treatment center headquartered in Fountain Valley, California, serving Orange County, Los Angeles County, and San Diego County since 2017. Licensed and certified by California's Department of Health Care Services, accredited by The Joint Commission, and a provider member of the National Association of Addiction Treatment Providers (NAATP), Asana specializes in dual-diagnosis care through PHP, IOP, outpatient, virtual, and sober-living programs. Asana Recovery has been named one of Newsweek's Best Addiction Treatment Centers for four consecutive years (2022–2025). Its mission is simple: saving lives, supporting families, and strengthening communities. Adam Shandrow Asana Recovery +1 (562) 972-3955 email us here Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

22 Jul 2026

·www.businesswire.com

Atropos Health Has 12 New Peer-Reviewed Research Studies Across Numerous Disease States Published in First Half of 2026

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the world’s largest creator of real-world evidence (RWE) for clinical decision making, today announced that it has contributed to 12 new studies in the first six months of 2026, powered by high-quality real-world data from the Atropos Evidence™ Network and Atropos Health’s AI-driven real world evidence tools. This new collection of research and conference presentations spans multiple disease states and demonstrates how real-world evidence accelerates clinically meaningful insights. A selection of these publications are summarized below and were presented at major conferences including ASCO 2026, the Society for Investigative Dermatology, the American Society of Clinical Psychopharmacology, ISPOR and Digestive Disease Week. Association between Semaglutide and Risk of Bone Fractures in Type 2 Diabetes - presented at ENDO2026 evaluated fracture incidence and body mass index (BMI) changes among type 2 diabetes patients treated with semaglutide versus dulaglutide or alternative weight loss drugs (phentermine/topiramate, bupropion/naltrexone). Overall, researchers found the semaglutide treatment was associated with a greater BMI reduction and 15% reduction in fracture incidence. Antidepressant Use and Melanoma Immunotherapy: An Unexpected Signal – presented at ASCO 2026 to examine whether SSRIs influence outcomes in patients with metastatic melanoma who receive immune checkpoint inhibitor therapy. mRNA vs. DNA COVID-19 Vaccines and Autoimmune Risk: Nuanced Findings from a Large Cohort – presented at the SID Annual Meeting 2026, the study found that there is a trend towards higher autoimmune risk after mRNA vaccination and should require additional research. Statins May Protect Against Intestinal Strictures in Crohn’s Disease – published in the Journal of Crohn’s and Colitis in March 2026, this study evaluated two national databases about how drug repurposing discovery, powered by real-world evidence can show secondary benefits. Alcohol Use Disorder: A Persistent Gap in Hospital Care – published in Alcohol and Alcoholism, the study showed that fewer than 3% of hospitalized patients with alcohol use disorder received any medication-assisted treatment. Machine Learning Targets Bipolar Disorder and Schizophrenia Treatment Selection – presented at ASCP Annual Meeting 2026. These two posters demonstrated how machine learning and real-world data can help identify which patients with bipolar 1 and schizophrenia could most likely benefit from the long-acting injectable, aripiprazole monohydrate. These insights will continue to grow as Alexandria®, the Atropos Evidence™ Library, which was already the largest source of novel medical content - with over 33M precision Evidence-Based Findings, is expected to grow to two billion pEBFs by the end of 2026. This increased scale will exceed all known medical evidence by 100x in volume. “By utilizing our high-throughput evidence-creation tools, we are delivering robust, peer-reviewed real-world evidence at a scale and speed previously unimaginable,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “These 12 new studies across diverse disease states demonstrate that we are doing more than generating data. We are filling the evidence gap with actionable, trusted insights that empower the entire healthcare ecosystem to make the best possible care decisions today. Atropos Health is fundamentally changing how care teams make daily medical decisions that are backed by high-quality evidence.” This library is enabling the entire healthcare ecosystem - clinicians, researchers, life science partners, and others - to generate precise answers to complex medical questions quickly and improve patient and medical outcomes based on content not available anywhere else. About Atropos Health Atropos Health is closing medicine's most consequential gap: actionable evidence to inform the vast majority of clinical decisions that are made without evidence. By generating real-world evidence from actual patient outcomes and data, Atropos Health is building the evidence infrastructure that clinicians, life science researchers and AI platforms need to practice, develop and inform medicine, grounded in what actually works. Better healthcare is only possible with evidence, and Atropos Health is working to make it available for every patient, in every healthcare decision, every day. Atropos Health does this via GENEVA OS®, the operating system across a robust network of real-world data; Alexandria, the world’s largest evidence library; and evidence generation tools such as ChatRWD®, Green Button® and the Atropos Evidence™ Agent. To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or X (Twitter).

Clinical StudyImmunotherapyASCO

16 Jul 2026

·allsci.com

Atai Therapeutics wins USD 2.73m NIH grant for non-hallucinogenic psychedelic compounds

Atai Therapeutics has received a USD 2.73 million UG3 cooperative agreement from the National Institute on Drug Abuse to advance non-hallucinogenic psychedelic-derived compounds for opioid use disorder (OUD), according to NIH Reporter. The award, granted under the UG3/UH3 mechanism that separates early optimization from later IND-enabling work, funds preclinical development of two lead chemical series rather than clinical testing. The company’s approach targets 5-HT2A/2C serotonin receptors, the same receptors activated by psilocybin, which has shown early signals of benefit in substance use disorders but carries hallucinogenic effects and 5-HT2B-related cardiac liabilities that complicate clinical use. Atai’s lead compounds, designated EGX-J and EGX-I, reportedly show roughly 100-fold selectivity for 5-HT2A/2C over 5-HT2B in preliminary studies, an approach intended to retain psilocybin’s polypharmacology while removing the need for supervised dosing sessions. Under the UG3 phase, Atai will optimize the compounds’ drug-like properties and select a development candidate; a subsequent UH3 phase would fund manufacturing scale-up, IND-enabling toxicology and repeat-dose efficacy studies ahead of a first-in-human Phase I trial. No clinical data exist yet for either series. The award reflects continued NIDA interest in medication development for OUD, an area where existing options—methadone, buprenorphine and naltrexone—carry adherence and misuse challenges. It also fits a broader pattern of “de-risked psychedelic” programs, alongside efforts by companies such as Delix Therapeutics and Gilgamesh Pharmaceuticals, seeking receptor-selective compounds without hallucinogenic effects. Principal investigator Glenn Short leads the project. Success in the UG3 phase, rather than the funding itself, will determine whether Atai’s non-hallucinogenic strategy advances toward human testing. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

PDC

100 Deals associated with Naltrexone

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Opium Dependence	United States	Alkermes, Inc.	12 Oct 2010
Alcoholism	United States	Alkermes, Inc.	13 Apr 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Opiate Overdose	Phase 3	United States	The University of California, San Francisco	10 Apr 2025
Methamphetamine abuse	Phase 3	United States	National Institute on Drug Abuse	01 Jul 2024
Methamphetamine dependence	Phase 3	United States	National Institute on Drug Abuse	01 Jul 2024
Obesity	Phase 3	United States	Yale University	13 Jan 2022
Fecal Incontinence	Phase 3	United States	Yale University	29 Jun 2021
Chronic pelvic pain syndrome	Phase 3	United States	Hershey Medical Center	16 Jan 2020
Endometriosis	Phase 3	United States	Hershey Medical Center	16 Jan 2020
Binge-Eating Disorder	Phase 3	United States	Yale University	07 Aug 2019
Opioid abuse	Phase 3	United States	Alkermes, Inc.	01 Apr 2016
Acquired Immunodeficiency Syndrome	Phase 3	United States	Yale University	01 Apr 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04450316 (CTgov)	Phase 2	Cystitis, Interstitial	29	Naltrexone (Low-dose Naltrexone)	jxmimhcsdt = nrtjurtqst mfnrbedtle (ebiopkktsw, akcqejhbov - rdxoxyenib) View more	-	10 Jul 2026
				Placebo (Placebo)	jxmimhcsdt = zvtezitmri mfnrbedtle (ebiopkktsw, dimbftlyrh - fftgexadgy) View more
NCT05458609 (CTgov)	Phase 3	Alcohol Use Disorder	8	Lemborexant 10 mg+Naltrexone (Lemborexant Plus Naltrexone)	wkmvcdsmei(xbdjudggyk) = ujeutzxwuj jeezosirzu (nusggjesbs, 16.77) View more	-	24 Mar 2026
				Naltrexone (Placebo Plus Naltrexone)	wkmvcdsmei(xbdjudggyk) = xjqhsqrlxf jeezosirzu (nusggjesbs, 21.94) View more
NCT03946111 (CTgov)	Phase 2/3	Binge-Eating Disorder \| Obesity	3	Naltrexone and Bupropion (Naltrexone/Bupropion)	mfuatfgfso(fyydzwhpbe) = umovkiriay fpazynojks (bpmzlvxegj, 0) View more	-	17 Dec 2025
				Placebo (Placebo)	mfuatfgfso(fyydzwhpbe) = qbootfqslc fpazynojks (bpmzlvxegj, 18.38) View more
NCT04817410 (CTgov)	Phase 1	Alcohol Use Disorder	30	Naltrexone (Oral Naltrexone)	spdmvugsvp(qpwfuddpqb) = hucnmmfviu kkuuxitepz (oxviphuppq, jcylnklafk - fvthdinrwu) View more	-	26 Aug 2025
				naltrexone (Enrolled Participant Characteristics)	vzjtmmywzr(hdzkwgpfyd) = kjldcflggk nwmkysmwdj (drowicnnmb, tkzhivttkj - zgjzahqnjl) View more
NCT02330419 (SayWhen, CTgov)	Phase 2	HIV Infections	120	Behavioral survey measurements: (Placebo)	jjqsrlwecu(oqavfmojxe) = xeyqswfsow helkhxnwwe (jkcbryoyqu, ebqowsolim - thqwwlhujj) View more	-	20 Apr 2025
				Behavioral survey measurements:+Naltrexone (Naltrexone)	jjqsrlwecu(oqavfmojxe) = xuegvbyxng helkhxnwwe (jkcbryoyqu, gpwwyrpfik - typyqdsfhm) View more
NCT01587196 (fMRI CURE, CTgov)	Phase 2	-	72	Vivitrol	gfyapdqoma = kkwyjqkzcr aukpvrhrjq (abwfkszkjj, qolgmnztzu - kfjqnzqwxy) View more	-	15 Oct 2024
NCT04547985 (PGD, CTgov)	Phase 4	-	9	Placebo (Placebo)	tnkxqarksr(niikbzpcly) = uwbsugotbv dwebwgxvsw (kcrnhmgnsl, 7.36) View more	-	28 Aug 2024
				Naltrexone HCl 50 MG Oral Tablet (Naltrexone)	tnkxqarksr(niikbzpcly) = xuwjdxzhbf dwebwgxvsw (kcrnhmgnsl, NA) View more
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	Not Applicable	Liver Diseases, Alcoholic	-	Naltrexone	dkyxkvfaqr(cwrsgfeolg) = kqodjplzxt bsfxojwtof (frhwmswpkh )	-	20 May 2024
				Acamprosate	dkyxkvfaqr(cwrsgfeolg) = oqnrwzjpin bsfxojwtof (frhwmswpkh )
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	Not Applicable	Liver Diseases, Alcoholic	-	Naltrexone	wbjshrrgwr(qtkhcjzzon) = the rate of AUD medication discontinuation for adverse events was similar in both groups (14% vs 12%) and none were stopped due to suspected DILI osvecpbtnk (wlpdzsrtby ) View more	-	20 May 2024
				Acamprosate
NCT02885311 (CTgov)	Phase 1/2	Alcoholism \| Alcohol-Related Disorders	27	Brief Advice (At-Risk Drinkers (AR))	ituwedmrob(qixkfxryvl) = ufzevcilyd sfblrpmbgo (tsascdmhqc, 4.1) View more	-	30 Oct 2023
				Brief Advice+Naltrexone (Problem Drinkers (PD))	ituwedmrob(qixkfxryvl) = lkckuxcnac sfblrpmbgo (tsascdmhqc, 8.0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis